Drug intelligence / Profile preview

siRNA-RMRP

Development stage
Preclinical
Lead developer
Peking University
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

siRNA-RMRP is a small interfering RNA (siRNA) designed to target and silence the long non-coding RNA (lncRNA) known as RMRP (RNA Component of Mitochondrial RNA Processing Endoribonuclease). In the context of relapsed and refractory acute myeloid leukemia (R/R AML), RMRP is significantly enriched in the mitochondria where it regulates oxidative phosphorylation, mitochondrial genome transcription, and epigenetics. By knocking down RMRP expression, siRNA-RMRP attenuates mitochondrial metabolic capacity, reduces mtDNA copy number, and induces mitophagy through pathways such as BNIP3L/Nix and PINK1/Parkin. This targeted depletion of RMRP has been shown to increase the sensitivity of AML cells to chemotherapy agents like Cytarabine and Doxorubicin, suggesting its potential as a therapeutic strategy to overcome chemoresistance.

Other names
RMRP siRNAsi-RMRP

Beyond the preview

Go deeper on siRNA-RMRP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on siRNA-RMRP.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call